×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Global Hypertriglyceridemia Treatment Market Report Analysis Bus
SOUTHEAST - NEWS CHANNEL NEBRASKA
Global key manufacturers (Acasti Pharma Inc, Akcea Therapeutics Inc, Allergan Plc, Alnylam Pharmaceuticals Inc, Arisaph Pharmaceuticals Inc, AstraZeneca Plc...
22 hours ago
After rebranding, Boston biotech Astria licenses dermatitis drug for $320M - Boston Business Journal
The Business Journals
Just over two years after it rebranded as an allergy and immunology company, Astria Therapeutics is adding a second drug to its clinical...
6 months ago
Catabasis Pharmaceuticals no more: Meet Astria Therapeutics, hoping to be a phoenix from the flames
Fierce Biotech
Catabasis Pharmaceuticals has culled staffers, axed pipeline meds and endured some major trial flops. Now, it's looking to hit the reset...
31 months ago
Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus
Business Wire
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of...
31 months ago
Catabasis Renames As Astria Therapeutics With New Disease Focus
Yahoo Finance
Once-struggling, Catabasis Pharmaceuticals Inc (NASDAQ: CATB) is looking to hit the reset button with a new name and focus.
31 months ago
WilmerHale Advises Catabasis Pharmaceuticals in Acquisition of Quellis Biosciences
WilmerHale
On January 29, 2021, Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, announced that it has acquired Quellis Biosciences Inc.,...
39 months ago
Catabasis, Now Renamed Astria, Working Toward HAE Trial Launch
Angioedema News
Catabasis, now renamed Astria Therapeutics, is working toward the launch of a proof-of-concept trial for HAE therapy STAR-0215 in 2022.
31 months ago
Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition (NASDAQ:ATXS)
Seeking Alpha
After edasalonexent's failure last year, Catabasis Pharmaceuticals pivoted to the HAE market through the acquisition of Quellis Biosciences.
34 months ago
Catabasis Pharmaceuticals Acquires Quellis Biosciences
FinSMEs
We recommend · Quellis Biosciences Raises $17M in Series A Financing · Catabasis Pharmaceuticals Completes $32.4M Series B Financing · Catabasis...
39 months ago
CATB Stock: Why Catabasis Pharma Stock Is Skyrocketing Today
InvestorPlace
Catabasis Pharma (CATB) stock is soaring higher on Friday after announcing its acquisition of Quellis Biosciences and a PIPE.
39 months ago